Education
About Us
Working with TipRanks
Follow Us
Ardelyx Inc (ARDX)
:ARDX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -28.15%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights significant revenue growth and strategic progress with IBSRELA and XPHOZAH. However, challenges such as market contractions, Medicare disruptions, and increased expenses were noted. The company's strong cash position and milestone achievement in China provide additional positives.Company Guidance
During the first quarter of 2025, Ardelyx reported a significant 61% year-over-year revenue growth, reaching $74 million. This growth was driven by robust performances from their commercial products, IBSRELA and XPHOZAH. IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by a strong prescription demand and strategic efforts to enhance prescriber adoption and patient access. The company reaffirmed its 2025 guidance of $240 million to $250 million in net sales and anticipates peak annual net sales revenue exceeding $1 billion for IBSRELA. XPHOZAH, despite market disruptions, grew by 30% from the previous year, excluding adjustments, totaling $23.4 million in net sales revenue. Ardelyx remains confident in achieving a peak sales target of $750 million for XPHOZAH, focusing on non-Medicare segments amid ongoing Medicare Part D changes. The company reported a net loss of $41.1 million and maintained a strong cash position of $214 million as of March 31, 2025.Significant Revenue Growth
Ardelyx reported a 61% increase in revenue, totaling $74 million compared to the same period last year.
IBSRELA's Strong Performance
IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by strong prescription demand and effective commercial execution.
XPHOZAH's Growth
XPHOZAH revenue grew by 30% compared to last year, with successful patient access across Medicare and non-Medicare segments.
Financial Milestone
Ardelyx earned a $5 million milestone from their partner in China following the approval of Tenapanor for hyperphosphatemia.
Strong Cash Position
As of March 31, 2025, Ardelyx had $214 million in cash, cash equivalents, and short-term investments.
ARDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $5.47 | $4.13 | -24.50% |
Feb 20, 2025 | $6.36 | $5.72 | -10.06% |
Oct 31, 2024 | $5.87 | $6.09 | +3.75% |
Aug 01, 2024 | $5.50 | $6.05 | +10.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ardelyx Inc (ARDX) report earnings?
Ardelyx Inc (ARDX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Ardelyx Inc (ARDX) earnings time?
Ardelyx Inc (ARDX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARDX EPS forecast?
ARDX EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.
